Response Evaluation Criteria in Solid Tumors [kritéria léčebné odpovědi]

topical
42
Terms

hodnocení léčebné odpovědi solidních nádorů
hodnocení odpovědi nádoru na léčbu
hodnocení RECIST
kritéria hodnocení odpovědi solidních nádorů
kritéria pro hodnocení léčebné odpovědi u nádorů
RECIST kritéria

 

RECIST

Persistent link   https://www.medvik.cz/link/D066066
Definition

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

DUI
D066066 MeSH Browser
CUI
M0592468
History note
2015
Public note
2015

E Analytical, Diagnostic and Therapeutic Techniques and Equipment
E01 Diagnosis 1 790
E01.789 Prognosis 9 661
E01.789.800 Treatment Outcome 21 703
E01.789.800.190 Disease-Free Survival 1 445
E01.789.800.238 Early Termination of Clinical Trials 16
E01.789.800.262 Pathologic Complete Response 7
E01.789.800.285 Progression-Free Survival 495
E01.789.800.379 Response Evaluation Criteria in Solid Tumors 42
E01.789.800.570 Sustained Virologic Response 19
E01.789.800.665 Therapeutic Index 6
E01.789.800.713 Treatment Expectations
E01.789.800.760 Treatment Failure 673

N Health Care
N04 Health Services Administration 1 738
N04.761 Quality of Health Care 2 492
N04.761.559 Outcome and Process Assessment, Health Care 1 870
N04.761.559.590 Outcome Assessment, Health Care 584
N04.761.559.590.800 Treatment Outcome 21 703
N04.761.559.590.800.190 Disease-Free Survival 1 445
N04.761.559.590.800.379 Early Termination of Clinical Trials 16
N04.761.559.590.800.427 Pathologic Complete Response 7
N04.761.559.590.800.474 Progression-Free Survival 495
N04.761.559.590.800.569 Response Evaluation Criteria in Solid Tumors 42
N04.761.559.590.800.665 Sustained Virologic Response 19
N04.761.559.590.800.713 Therapeutic Index 6
N04.761.559.590.800.737 Treatment Expectations
N04.761.559.590.800.760 Treatment Failure 673
N05 Health Care Quality, Access, and Evaluation 685
N05.715 Quality of Health Care 2 492
N05.715.360 Health Care Evaluation Mechanisms 200
N05.715.360.575 Outcome and Process Assessment, Health Care 1 870
N05.715.360.575.575 Outcome Assessment, Health Care 584
N05.715.360.575.575.800 Treatment Outcome 21 703
N05.715.360.575.575.800.190 Disease-Free Survival 1 445
N05.715.360.575.575.800.379 Early Termination of Clinical Trials 16
N05.715.360.575.575.800.427 Pathologic Complete Response 7
N05.715.360.575.575.800.474 Progression-Free Survival 495
N05.715.360.575.575.800.569 Response Evaluation Criteria in Solid Tumors 42
N05.715.360.575.575.800.665 Sustained Virologic Response 19
N05.715.360.575.575.800.713 Therapeutic Index 6
N05.715.360.575.575.800.737 Treatment Effect Heterogeneity
N05.715.360.575.575.800.749 Treatment Expectations
N05.715.360.575.575.800.760 Treatment Failure 673

Add